The following published clinical studies and scientific papers have shown features and benefits of the CARMEDA® BioActive Surface:
1) Olsson P, Sanchez J, Mollnes TE, et al. On the blood compatibility of end-point immobilized heparin.
2) Weber N, Wendel HP, Ziemer G, et al. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption.
3) Pasche B, Kodama K, Larm O, et al. Thrombin inactivation on surfaces with covalently bonded heparin.
4) Kodama K, Pasche B, Olsson P, et al. Antithrombin III binding to surface immobilized heparin and its relation to FXa inhibition.
5) Sanchez J, Elgue G, Riesenfeld J, et al. Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence.
6) Sanchez J, Elgue G, Riesenfeld J, et al. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin.
7) Mottaghy K, Oedekoven B, Pöppel K, et al. Heparin-coated versus non-coated surfaces for extracorporeal circulation.
8) Øvrum E, Tangen G, Tølløfsrud S, et al. Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: An analysis of nearly 6000 patients undergoing coronary artery bypass grafting.
9) Mollnes TE, Videm V, Christiansen D, et al. Platelet compatibility of an artificial surface modified with functionally active heparin.
10) Kocsis JF, Llanos G, Holmer E. Heparin-coated stents.
11) Lin PH, Bush RL, Yao Q, et al. Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model.
12) Fukutomi M, Kobayashi S, Niwaya K, et al. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
Artif Organs 1996, 20(7): 767-776
13) Gurbel PA, Bliden KP. Platelet activation after stenting with heparin-coated versus noncoated stents.
14) Mollnes TE, Riesenfeld J, Garred P, et al. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin.
15) Kopp R, Mottaghy K, Kirschfink M. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces.
16) Lappegård KT, Fung M, Bergseth G, et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
17) Lappegård KT, Bergseth G, Riesenfeld J, et al. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent.
18) Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
19) Appelgren P, Ransjö U, Bindslev L, et al. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial.
20) Jain G, Allon M, Saddekni S, et al. Does heparin coating improve patency or reduce infection of tunneled dialysis catheters?
21) Lin PH, Chen C, Bush RL, et al. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model.
22) Freeman J, Chen A, Weinberg RJ, et al. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic canine femoral artery bypass model.
23) Riesenfeld J, Ries D, Hetzer R. Analysis of the heparin coating of an EXCOR Ventricular Assist Device after 855 days in a patient.
Society for Biomaterials Transactions of the 32rd annual meeting 2007, (85)
24) Begovac PC, Thomson RC, Fisher JL, et al. Improvements in GORE-TEX Vascular Graft Performance by Carmeda BioActive Surface Heparin Immobilization.
25) Werkkala K, Jokkinen JJ, Soininen L, et al. Clinical durability of the CARMEDA BioActive Surface in EXCOR ventricular assist device pumps.
26) Hårdhammar PA, van Beusekom HM, Emanuelsson HU, et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries.
27) Kaufmann E, Hennig M, Loebe, et al. Improving the antithrombogenity of artificial surfaces through heparin coating - Clinical experience with the pneumatic extracorporeal Berlin Heart assist device.
Cardiovascular Engineering 1996, 1(1): 40-44
28) Samson RH, Morales R, Showalter DP, et al. Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison.
29) Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian Propaten® trial - 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses - a randomised clinical controlled multi-centre trial.
30) Ashfaq A, Soroya MS, Iyengar A, Federman M, Reemtsen BL. Heparin-coated grafts reduce mortality in pediatric patients receiving systemic-to-pulmonary shunts.
31) Gupta V, Aravamuthan BR, Baskerville S, et al. Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, real world registry.
32) Gore S, Andersson J, Biran R, et al. Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption.
33) Biran R, Pond D. Heparin coatings for improving blood compatibility of medical devices.